ORIC Pharmaceuticals, Inc. ORIC R2K
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -15.1% CAGR over 5 years.
- Trading 41.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ORIC ORIC Pharmaceuticals, Inc. R2K | 8.45 | - | $874.72M | - | -36.81% | -42.57% | - | -15.09% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 32.72M | 39.06M | 36.67M | 34.55M | 39.62M |
| Operating Income | -6.35M | -6.36M | -7.10M | -9.18M | -11.12M | -25.60M | -16.55M | -21.06M | -18.46M | -23.26M | -20.70M | -25.69M | -25.68M | -24.99M | -28.68M | -28.99M | -36.02M | -38.32M | -32.72M | -39.06M | -36.67M | -34.55M | -39.62M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -32.42M | -38.75M | -36.38M | -34.23M | -39.35M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -30.02M | -36.35M | -32.59M | -30.50M | -35.77M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -6.01M | -5.96M | -6.55M | -8.87M | -11.02M | -25.55M | -16.51M | -21.01M | -18.43M | -23.16M | -20.29M | -24.83M | -23.95M | -22.94M | -25.48M | -25.01M | -31.96M | -34.57M | -30.02M | -36.35M | -32.59M | -30.50M | -35.77M |
| Diluted EPS | - | - | - | - | - | - | - | -0.57 | -0.47 | -0.59 | -0.51 | -0.63 | -0.53 | -0.50 | -0.44 | -0.37 | -0.45 | -0.49 | -0.42 | -0.47 | -0.33 | -0.30 | -0.34 |
| R&D Expense | 5.21M | 5.04M | - | 7.25M | 7.72M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | 86.77M | 110.78M | 142.90M | 143.00M |
| Operating Income | -22.37M | -28.57M | -74.19M | - | -86.77M | -110.78M | -142.90M | -143.00M |
| EBITDA | - | - | - | - | -85.80M | -109.75M | -141.79M | -141.78M |
| Interest Expense | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | -89.12M | -100.70M | -127.85M | -129.47M |
| Tax Provision | - | - | - | - | - | - | - | - |
| Net Income | -21.36M | -26.88M | -73.70M | - | -89.12M | -100.70M | -127.85M | -129.47M |
| Diluted EPS | - | - | - | -2.07 | -2.25 | -1.96 | -1.83 | - |
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -15.09% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +3.43% |
| 6 Months: | -27.28% |
| 3 Months: | -37.17% |
| 1 Month: | -10.49% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 94.09M | 299.00M | - | 247.18M | 252.01M | 274.14M | 408.89M |
| Current Assets | - | - | - | - | - | 210.46M | 212.60M | 262.25M | 288.47M |
| Cash & Equivalents | - | - | 89.16M | 78.45M | - | 66.84M | 23.38M | 59.41M | 45.67M |
| Inventory | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | 6.12M | 9.22M | - | 24.83M | 27.92M | 31.02M | 24.53M |
| Current Liabilities | - | - | 5.35M | 9.00M | - | 15.39M | 20.46M | 24.85M | 20.42M |
| Long Term Debt | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | 2.66M | 2.75M | 3.18M | 3.33M |
| Total Equity | -43.61M | -64.43M | -90.08M | 289.78M | - | 222.35M | 224.09M | 243.12M | 384.36M |
| Shares Outstanding | - | - | - | - | - | 45.09M | 54.87M | 71.02M | 98.53M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -20.68M | -23.53M | -45.27M | - | -75.14M | -85.69M | -112.66M | -110.97M |
| Investing Cash Flow | -508.00K | -768.00K | -215.96M | - | -109.25M | -43.40M | 22.14M | -148.03M |
| Financing Cash Flow | 38.01M | 70.82M | 250.51M | - | 25.23M | 85.66M | 126.55M | 245.26M |
| Capital Expenditure | -525.00K | -768.00K | -667.00K | - | -2.08M | -849.00K | -1.19M | -712.00K |
| Free Cash Flow | -21.21M | -24.30M | -45.94M | - | -77.22M | -86.54M | -113.85M | -111.68M |
| Net Change in Cash | - | - | - | - | -159.17M | -43.43M | 36.02M | -13.74M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - |
| ROE % | 33.2% | 29.8% | -25.4% | - | -40.1% | -44.9% | -52.6% | -33.7% |
| ROCE % | - | -32.2% | -25.6% | - | -37.4% | -47.8% | -57.3% | -36.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Nextech Invest, Ltd. | 6.92% | 7.16M | $60.52M |
| 2 | EcoR1 Capital, LLC | 6.50% | 6.73M | $56.85M |
| 3 | Blackrock Inc. | 5.78% | 5.98M | $50.57M |
| 4 | Viking Global Investors, L.P. | 5.63% | 5.82M | $49.22M |
| 5 | Price (T.Rowe) Associates Inc | 5.20% | 5.39M | $45.53M |
| 6 | Pfizer Inc | 4.62% | 4.78M | $40.39M |
| 7 | SR One Capital Management, LP | 4.36% | 4.51M | $38.15M |
| 8 | Alkeon Capital Management LLC | 4.35% | 4.50M | $38.06M |
| 9 | Venrock Adviser, LLC | 4.17% | 4.32M | $36.50M |
| 10 | NEA Management Company, LLC | 3.98% | 4.12M | $34.80M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ORIC